MILFORD, Mass., Feb. 13 Waters Corporation(NYSE: WAT) and Vanderbilt University Medical Center jointly announcecollaborative research efforts using Waters(R) MALDI SYNAPT(TM) HighDefinition MS(TM) (HDMS(TM)) System for enhanced tissue imaging capabilitiesfor oncology research within the University's Mass Spectrometry ResearchCenter.
Researchers at the Vanderbilt University Medical Center are focused onnovel mass spectrometry (MS) approaches to identify and visualize proteinexpression changes in cells as they transition from a healthy state throughvarious stages of cancer.
"The goal of tissue imaging is to provide a window into the changes in thecellular proteome in disease," said Professor Richard Caprioli, Director ofMass Spectrometry Research Center at Vanderbilt University Medical Center. "Welook forward to evaluating the use of ion mobility for enhanced MALDI imagingcombined with high resolution, high sensitivity, orthogonal time-of-flight(Tof) mass spectrometry. Ultimately, we hope that enhanced tissue imagingtechniques will provide data sets to be mined for diagnostic and prognosticinformation related to the various stages of cancer."
The SYNAPT HDMS system is the only commercial instrument to incorporatehigh efficiency ion mobility separation in a dual ionization mass spectrometergiving scientists maximum analytical power for discovery research challenges.
"This Vanderbilt University collaboration is the latest example of howWaters works with leading researchers to push the limits of science," saidBrian Smith, Vice President, Mass Spectrometry Operations for Waters Division."By working with the preeminent research group in the field, we expect toderive significant insight into the power of MALDI tissue imaging forbiological applications and its potential for diagnostic purposes; not tomention the potential positive impact from better understanding the cellularproteome of one of world's most devastating diseases."
Waters introduced the SYNAPT HDMS System at the American Society of MassSpectrometry annual meeting in Seattle in June of 2006. It is the firstcommercially-available mass spectrometer with the ability to analyze ions bytheir size, shape and charge in addition to mass. Waters added MALDI-capability to the SYNAPT HDMS System in 2007 and at PITTCON(R) 2007, theWaters SYNAPT High Definition MS System received the PITTCON Editor's GoldAward as Best New Product as well as Instrument Business Outlook newsletter'stop prize for best new product. For more information on Waters SYNAPT HighDefinition MS System, visit www.waters.com/HDMS.
About Vanderbilt University Medical Center
Vanderbilt University Medical Center is home to the Vanderbilt UniversitySchool of Medicine and Vanderbilt University School of Nursing, as well asfour separate hospitals and a growing basic research enterprise.
Vanderbilt University Hospital, The Monroe Carell Jr. Children's Hospitalat Vanderbilt, the Psychiatric Hospital at Vanderbilt and the VanderbiltStallworth Rehabilitation Hospital combined for over 46,000 inpatientadmissions during fiscal year 2007. Vanderbilt's outpatient clinics combinedto treat over 1.1 million patients during this same period.
The Vanderbilt School of Medicine placed 18th among 125 medical schools inU.S. News & World Report's 2008 survey, "America's Best Graduate Schools."
The Medical School's reputation for outstanding research is reflected inthe amount of federal and private support it receives. The School of Medicineranks 15th overall out of 125 medical schools in the receipt of funding fromthe National Institutes of Health. Support for competitive research grants wasalmost $390 million in fiscal year 2007.
About Waters Corporation (www.waters.com)
Waters Corporation (NYSE: WAT) creates business advantage for laboratory-dependent organizations by deliver